Stock listing
LSE:THAT Thalia Therapeutics PLC Share Price
Home listing (LSE) of Thalia Therapeutics PLC
Follow Thalia Therapeutics PLC into a list and get an email when it puts out news.
Share price · LSE:THAT
0.575p GBX (pence) 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- 0.562p – 0.575p GBX (pence)Nov 20, 2026
- Volume
- 427,173 sharesNov 20, 2026
- Market cap
- £10.21M GBPAt the close on Nov 20, 2026 · price × 1.78B shares outstanding
- 52-week range
- 0.400p – 0.950p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £4,983 GBPMedian day 405,366 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:THAT · Home | 0.575p GBX (pence) | 0.000 (0.0%) | 427,173 | 0.575p | 0.575p | 0.562p | 0.575p | Close on Nov 20, 2026 |
| Frankfurt:0GO | €0.0050 EUR | 0.0000 (0.0%) | — | €0.0050 | €0.0050 | €0.0050 | €0.0050 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:THAT · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.562p | 427,173 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 66,481 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.565p | 1,011,418 | |
| 0.575p | 0.000 | 0.0% | 0.570p | 0.600p | 0.550p | 228,872 | |
| 0.575p | 0.000 | 0.0% | 0.535p | 0.600p | 0.500p | 2,587,591 | |
| 0.575p | 0.000 | 0.0% | 0.551p | 0.600p | 0.550p | 3,237,358 | |
| 0.575p | +0.025 | +4.5% | 0.585p | 0.600p | 0.550p | 1,619,882 | |
| 0.550p | 0.000 | 0.0% | 0.550p | 0.550p | 0.518p | 2,011,818 | |
| 0.550p | -0.025 | -4.3% | 0.552p | 0.600p | 0.500p | 3,702,796 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 54,102 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.551p | 371,130 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.551p | 27,087 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 14,294 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 14,294 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 20,000 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 752,173 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.575p | 0.550p | 300,000 | |
| 0.575p | 0.000 | 0.0% | 0.600p | 0.600p | 0.573p | 1,259,868 | |
| 0.575p | 0.000 | 0.0% | 0.600p | 0.600p | 0.573p | 536,216 | |
| 0.575p | -0.025 | -4.2% | 0.600p | 0.600p | 0.571p | 142,491 | |
| 0.600p | 0.000 | 0.0% | 0.600p | 0.630p | 0.576p | 18,295 | |
| 0.600p | -0.025 | -4.0% | 0.603p | 0.603p | 0.600p | 430,337 | |
| 0.625p | +0.001 | +0.2% | 0.625p | 0.635p | 0.603p | 170,000 | |
| 0.624p | -0.001 | -0.2% | 0.624p | 0.624p | 0.600p | 635,370 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 66,954 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.639p | 0.600p | 31,491 | |
| 0.625p | 0.000 | 0.0% | 0.650p | 0.650p | 0.603p | 1,000,347 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.625p | 0.600p | 64,592 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.625p | 0.600p | 42,536 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 9,115 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 398,164 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 648,882 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.625p | 0.600p | 121,919 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 502,753 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.625p | 156,922 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 1,416,838 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.613p | 1,062,619 | |
| 0.625p | +0.025 | +4.2% | 0.600p | 0.650p | 0.600p | 1,885,245 | |
| 0.600p | 0.000 | 0.0% | 0.600p | 0.650p | 0.550p | 1,251 | |
| 0.600p | +0.025 | +4.3% | 0.600p | 0.650p | 0.550p | 1,928,060 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.599p | 0.550p | 1,015,064 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.600p | 0.550p | 253,537 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.600p | 0.550p | 565,424 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.600p | 0.550p | 770,787 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.600p | 0.550p | 187,256 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.600p | 0.550p | 419,410 | |
| 0.575p | 0.000 | 0.0% | 0.575p | 0.600p | 0.550p | 756,020 | |
| 0.575p | +0.025 | +4.5% | 0.600p | 0.650p | 0.550p | 7,773,544 | |
| 0.550p | 0.000 | 0.0% | 0.550p | 0.600p | 0.500p | 23,797 | |
| 0.550p | 0.000 | 0.0% | 0.550p | 0.600p | 0.516p | 2,584,147 | |
| 0.550p | 0.000 | 0.0% | 0.550p | 0.600p | 0.550p | 2,306 | |
| 0.550p | 0.000 | 0.0% | 0.550p | 0.600p | 0.500p | 38,722 | |
| 0.550p | -0.025 | -4.3% | 0.575p | 0.600p | 0.500p | 2,574,838 | |
| 0.575p | -0.050 | -8.0% | 0.625p | 0.650p | 0.550p | 4,360,358 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.601p | 66,505 | |
| 0.625p | 0.000 | 0.0% | 0.625p | 0.650p | 0.600p | 405,366 | |
| 0.625p | -0.025 | -3.8% | 0.650p | 0.650p | 0.600p | 434,717 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.675p | 0.605p | 2,031,397 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.700p | 0.621p | 788,379 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.700p | 0.600p | 765,353 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.700p | 0.600p | 29,312 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.700p | 0.600p | 140,490 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.700p | 0.620p | 168,214 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.650p | 0.650p | 107,932 | |
| 0.650p | 0.000 | 0.0% | 0.650p | 0.700p | 0.600p | 124,736 |
Splits
2 splits since 2015 · LSE:THAT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- LSE:THAT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Nov 16, 2026
Promising Interim Phase I Data for miRisten in AML
Latest earnings call · Sep 30, 2026
Thalia Therapeutics (LSE:THAT) — Interim results for the six months ended 30 June 2026
Replay and transcript
Latest news
Promising Interim Phase I Data for miRisten in AML
Nov 16, 2026
Closed 0.575p (0.0%) on Nov 16, 2026
Lipisiran™ cardiovascular in vitro study completed
Nov 11, 2026
Closed 0.575p (+4.5%) on Nov 11, 2026
Clinical Trial Agreement signed for miRisten
Nov 9, 2026
Closed 0.55p (-4.3%) on Nov 9, 2026
Interim Results
Sep 30, 2026
Closed 0.625p (0.0%) on Sep 30, 2026
New Patent Granted for miRisten in China
Sep 29, 2026
Closed 0.625p (+4.2%) on Sep 29, 2026
RNA gene-silencing cardiovascular program advances
Sep 25, 2026
Closed 0.60p (+4.3%) on Sep 25, 2026
Business Update and Notice of Results
Sep 15, 2026
Closed 0.575p (+4.5%) on Sep 15, 2026
Grant of Director Share Options
Jul 23, 2026
Closed 0.70p (0.0%) on Jul 23, 2026
Result of AGM and Completion of Acquisition
Jul 17, 2026
Closed 0.65p (0.0%) on Jul 17, 2026
Acquisition and £2.75 million Fundraise
Jun 24, 2026
Closed 0.675p (+17.4%) on Jun 24, 2026
Thalia Therapeutics PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 134 in all · newest Nov 16, 2026 · oldest 2017
- Calls
- 4 calls with a replay · 4 with a transcript · latest Sep 30, 2026
- Decks
- 1 deck · latest Oct 2, 2023
Where Thalia Therapeutics PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:THAT · Home listing · This page | LSE | United Kingdom | GBX |
| LS Exchange:A2DQES | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2DQES | Lang & Schwarz | Germany | EUR |
| Stuttgart:0GO | Stuttgart | Germany | EUR |
| AQUIS:THAT.GB | AQUIS | United Kingdom | GBX |
| Frankfurt:0GO | Frankfurt | Germany | EUR |
Valuation
EV/sales 1,199× against a median of 2.2×: the highest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £8.71M GBP
- P/E
- Loss
- EV/sales
- 1,199×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 4.2×
- Gross margin
- 100.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Thalia Therapeutics PLC · LSE:THAT | US$13.36M | US$11.39M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.47M | US$15.05M | n/a | n/a | 52.8× | 3.6× | n/a | 0.4× | n/a |
| BioInvent International AB · OMXSTO:BINV | US$13.45M | −US$6.62M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Celyad Oncology SA · EURONEXT:CYAD | US$13.31M | US$13.21M | 14.6× | 573× | n/a | 9.7× | n/a | 0.0× | n/a |
| Defence Therapeutics Inc Class A · CSE:DTC | US$13.27M | US$13.16M | n/a | n/a | n/a | 5.4× | n/a | 0.5× | 0.74 |
| Tvardi Therapeutics, Inc. · NASDAQ:TVRD | US$13.22M | −US$9.05M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.89 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.22M | −US$16.66M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Median of the others | US$13.38M | US$12.05M | 7.5× | 2.2× | 52.8× | 0.9× | −204.1% | 0.0× | 1.38 |
Team and board
Officers
| Officer | Role |
|---|---|
| David H Solomon | Chief Executive Officer |
| Luke Cairns | Chief Financial Officer |
| Sarah Hollins | Investor Relations |
Board
| Director | Role |
|---|---|
| Chris Britten | Non-Executive Chairman |
| Alastair Smith | Non-Executive Director |
| Edward Wardle | Non-Executive Director |
| Michael G. Palfreyman | Non-Executive Director |
Events
| Call | When | Status |
|---|---|---|
| Thalia Therapeutics (LSE:THAT) — Interim results for the six months ended 30 June 2026 | Wed, Sep 30, 2026 · 9:00 AM ET | Replay |
| Thalia Therapeutics (LSE:THAT) — Investor Presentation | Wed, Jun 24, 2026 · 9:00 AM ET | Replay |
| Thalia Therapeutics (LSE:THAT) — Interim results for the six months ended 30 June 2025 | Thu, Sep 25, 2025 · 9:00 AM ET | Replay |
| Thalia Therapeutics (LSE:THAT) — Investor Webinar | Tue, Feb 04, 2025 · 4:30 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 18 slides | Oct 2, 2023 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Update: £2.75M Buyers: NLC Health Impact Fund Cooperatof U.A. (29,166,667 Second Fundraise Shares) | Jul 17, 2026 | US$3.7M |
| Private placement of second Issue Shares (ordinary shares) with Fundraise Warrants Closed: private placement | Apr 22, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.26K | 7.28K | 1.95K | 0 | 0 | 1.16M | ||||
| Cost of revenue | 934.0K | |||||||||
| Gross profit | 7.26K | 7.28K | 1.95K | 221.0K | ||||||
| Research and development | 91.9K | 390.4K | 619.4K | 577.5K | 1.18M | 900.4K | 216.9K | 846.2K | 409.8K | |
| Selling, general and administrative | 795.4K | 551.6K | 718.0K | 615.7K | 663.9K | 664.0K | 730.4K | 643.7K | 316.6K | 249.0K |
| Operating income | -1.10M | -1.22M | -1.43M | -1.19M | -1.84M | -1.56M | -947.0K | -1.49M | -726.0K | -28.0K |
| Depreciation and amortization | 89.2K | 228.5K | 236.6K | 171.9K | 161.1K | 281.3K | 6.00K | |||
| EBITDA | -1.34M | -964.5K | -1.61M | -775.1K | -1.33M | -444.7K | -22.0K | |||
| Interest expense | 1.96K | 1.39K | 981 | 5.30K | 5.86K | |||||
| Income before tax | -1.10M | -1.22M | -1.43M | -1.19M | -1.84M | -1.57M | -949.0K | -1.39M | -1.93M | -22.0K |
| Income tax | 104.1K | -101.0K | -148.0K | -164.0K | -298.0K | -262.0K | -72.4K | -206.0K | -89.9K | -14.4K |
| Net income | -1.21M | -1.06M | -1.27M | -1.03M | -1.54M | -1.30M | -876.0K | -1.19M | -1.84M | -22.0K |
| Earnings per share, basic | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.08M | 626.0K | 1.03M | 1.92M | 1.78M | 3.56M | 965.8K | 793.1K | 1.33M | 172.0K |
| Receivables | 73.7K | 134.7K | 176.4K | 209.6K | 551.3K | 254.8K | 87.5K | 265.1K | 163.0K | 23.2K |
| Inventory | -265.1K | -132.7K | 232.0K | |||||||
| Current assets | 1.17M | 775.8K | 1.21M | 2.17M | 2.34M | 3.83M | 1.07M | 1.07M | 1.46M | 601.0K |
| Goodwill | 0 | 61.2K | 0 | |||||||
| Total assets | 1.17M | 775.8K | 1.28M | 2.17M | 2.34M | 3.83M | 1.07M | 1.07M | 1.46M | 1.12M |
| Accounts payable | 27.0K | 23.3K | 20.2K | 35.8K | 180.3K | 116.9K | 27.2K | 113.1K | 79.5K | |
| Current liabilities | 98.0K | 124.4K | 81.7K | 77.9K | 212.7K | 169.1K | 77.7K | 190.1K | 179.2K | 77.0K |
| Total debt | 204.9K | |||||||||
| Total liabilities | 98.0K | 124.4K | 81.7K | 77.9K | 212.7K | 169.1K | 77.7K | 190.1K | 179.2K | 77.0K |
| Shareholders' equity | 1.07M | 647.6K | 1.13M | 2.09M | 2.13M | 3.66M | 987.3K | 879.9K | 1.28M | 1.04M |
| Shares outstanding | 724.4M | 340.9M | 242.9M | 186.4M | 181.1M | 136.3M | 100.2M | 91.3M | 64.8M | 34.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.16M | -971.5K | -1.21M | -828.3K | -1.77M | -1.38M | -806.0K | -1.34M | -950.8K | -376.0K |
| Capital spending | -5 | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -1.16M | -971.5K | -1.21M | -828.3K | -1.77M | -1.38M | -806.0K | -1.34M | -950.8K | -376.0K |
| Cash from investing | 781 | 27.7K | 403.0K | -39.0K | ||||||
| Cash from financing | 1.61M | 570.4K | 315.9K | 963.8K | 677 | 3.97M | 978.6K | 783.4K | 1.85M | 119.9K |
| Change in cash | 453.3K | -401.1K | -892.4K | 135.5K | -1.77M | 2.59M | 172.6K | -533.1K | 1.31M | -415.0K |
Cap table
Built by 6ix from Thalia Therapeutics PLC’s releases · as of Apr 22, 2025
- Common shares
- 1,775,720,897
- Fully diluted
- 1,775,720,897
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,775,720,897 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,775,720,897 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alastair Smith | Non-Executive Director · Since at least Sep 30, 2026 |
| Chris Britten | Non-Executive Chairman · Since at least Sep 30, 2026 |
| David H Solomon | Chief Executive Officer · Since at least Sep 30, 2026 |
| Edward Wardle | Non-Executive Director · Since at least Jul 17, 2026 |
| Luke Cairns | Chief Financial Officer · Since at least Sep 30, 2026 |
| Michael G. Palfreyman | Non-Executive Director · Since at least Sep 30, 2026 |
| Sarah Hollins | Investor Relations · Since at least Apr 20, 2026 |
Log in to ask 6ix AI your own questions about Thalia Therapeutics PLC.